ClC-1 inhibition for improvement of muscle function in CMT webinar

NMD Pharma is shining a spotlight on the European CMT Federation (ECMTF), a nonprofit organization dedicated to uniting Charcot-Marie-Tooth disease (CMT) advocacy groups in Europe and from across the world.

Founded in 2016, the ECMTF currently has currently has 12 Full Members and 9 Associate Members, each of which are dedicated to supporting those affected by CMT across European and global geographies. Their motto – “together we are stronger” – is exemplified through each of the Federation’s mission points, including their primary goals of working collaboratively to fund life-changing research projects, raise awareness of this Rare Disease, and support the formation of new organizations in countries where an advocacy group does not yet exist.

To learn more about the ECMTF’s efforts to bring CMT into the spotlight, including their annual CMT Awareness campaign.

At NMD Pharma, we are proud to be invited by ECMTF’s CMT Awareness Webinar Series to raise the awareness of ongoing clinical trials in CMT to help those impacted by the disease. We look forward to partnering actively with ECMTF in their future activities in events to help the CMT community!

 You can find the webinar here:

Previous
Previous

NMD Pharma publishes new data on the role of ClC-1 inhibition in Charcot-Marie-Tooth in the Annals of Clinical and Translational Neurology

Next
Next

NMD Pharma Initiates Phase 2 Study of NMD670 in Patients with Charcot-Marie-Tooth Disease Type 1 and 2